In vitro activity of tigecycline: MICs, MBCs, time-kill curves and post-antibiotic effect

Journal of Chemotherapy

Volumn 20, Issue 5, 2008, Pages 577-580

  Noviello, S ^a   Ianniello, F ^a   Leone, S ^a   Fiore, M ^a   Esposito, Silvano ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Clinica Malattie Infettive   (Italy)

Author keywords

PAE; Tigecycline; Time kill

Indexed keywords

GLYCYLCYCLINE DERIVATIVE; TIGECYCLINE;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; ENTEROBACTER; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTANTIBIOTIC EFFECT; STAPHYLOCOCCUS AUREUS;

EID: 57049125761     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.5.577     Document Type: Article

References (13)

1. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect 2004; 49: 201-209.
2. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials for complicated skin and skin structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41(Suppl. 5), S315-S332.
3. Hoban DS, Bouchillon BJ, Johnson J, Dowzicky M. In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (TEST Program 2004). Diagn Microbiol Infect Dis 2005; 52: 215-227.
4. Jones CH, Petersen PJ. Tigecycline: a review of preclinical and clinical studies of the first-in class glycylcycline antibiotic. Drugs Today 2005; 637-659.
5. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antimicrobial activities of a novel glycylcycline, the 9-tbutylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43:738-744.
6. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards: M/-A7. Wayne, PA: Clinical and laboratory Standards Institute, 2006.
7. Bradford PA, Petersen PJ, Young M et al. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 2005; 49: 3903-3909.
8. NCCLS. Methods for determining bactericidal activity of antimicrobial agents: Approved guidelines M26-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 19, 1999.
9. Craig WA, Gudmundsson S. Postantibiotic effect. In Lorian V. ed. Antibiotics in Laboratory Medicine. Baltimore: Williams & Wilkins, 1996: 296-305.
10. Food and Drug Administration. Class II special controls guidance document: antimicrobial susceptibility test systems (AST)-guidance for industry. U.S. Food and Drug Administration, Washington, DC, [Online] 2003. http://www.fda.gov/cdrh/oivd/quidance/631.pdf.
11. Hoellman DB, Pankuch GA, Jacobs MR et al. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 2000; 44: 1085-1088.
12. van Ogtrop ML, Andes D, Stamstad TJ et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44: 943-949.
13. Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002; 22, 1517-1523.